In addition, we also observed that ZNF667-AS1 could be used as a molecular marker for distinguishing glioma specimens with advanced stages from glioma specimens with early stages with an AUC of 0.7742 (95% CI: 0.6990-0.8494; p < 0.01, Figure 3(b)). Here, ZNF667 is linked to central nervous system cancer.